<DOC>
	<DOCNO>NCT01852071</DOCNO>
	<brief_summary>In current study , investigator determine whether use lentiviral vector ( base HIV-1 ) effective safer gene transfer hematopoietic stem cell compare previous gene transfer vector base murine ( mouse ) retroviruses ADA-deficient SCID . The level gene transfer blood cell immune function measure endpoint .</brief_summary>
	<brief_title>Autologous Transplant EFS-ADA Modified Bone Marrow Cells ADA-Deficient Severe Combined Immunodeficiency ( SCID )</brief_title>
	<detailed_description>The study open twenty ( 20 ) infant child diagnose ADA-deficient SCID medically eligible , HLA-identical sibling donor bone marrow transplantation . The EFS-ADA lentiviral vector human ADA cDNA use transduce autologous CD34+ cell bone marrow subject . The subject receive 4 mg/kg busulfan prior re-infusion gene-modified cell . Safety primary endpoint . During follow-up phase , investigator determine whether cell engraft produce mature cell contain express correct ADA gene absence PEG-ADA enzyme replacement therapy ( ERT ) , withhold Day +30 follow transplant . Efficacy study evaluate level immune reconstitution begin first year continue second year . This Phase I/II clinical trial perform Mattel Children 's Hospital , UCLA Mark O. Hatfield Clinical Research Center , NIH .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<criteria>Children ≥ 1.0 month age diagnosis ADAdeficient SCID base A . Decreased ADA enzymatic activity erythrocyte , leukocyte , skin fibroblast , culture fetal cell level consistent ADAdeficient SCID determine reference laboratory confirm ADA gene mutation ( ) know cause disease , AND B . Evidence severe combine immunodeficiency base either : 1 . Family history first order relative ADA deficiency clinical laboratory evidence severe immunologic deficiency , OR 2 . Evidence severe immunologic deficiency subject prior institution immune restorative therapy , base 1. lymphopenia ( absolute lymphocyte count &lt; 400 cells/mcL ) OR absence low number T cell ( absolute CD3+ count &lt; 300 cells/mcL ) OR 2. severely decreased T lymphocyte blastogenic response phytohemagglutinin ( either &lt; 10 % low limit normal control diagnostic laboratory , &lt; 10 % response normal control day , stimulation index &lt; 10 ) Ineligible match sibling allogeneic bone marrow transplantation : absence medically eligible HLAidentical sibling , normal immune function , may serve allogeneic bone marrow donor Signed write informed consent accord guideline IRB ( UCLA Office Human Research Protection Program National Human Genome Research Institute ( NHGRI ) Institutional Review Board 1 . Age ≤ 1.0 month Appropriate organ function outline must observe within 8 week enter trial . 2 . Hematologic 1 . Anemia ( hemoglobin &lt; 10.5 g/dl &lt; 2 year age , &lt; 11.5 g/dl &gt; 2 year age ) . 2 . Neutropenia ( absolute granulocyte count &lt; 500/mm3 . 3 . Thrombocytopenia ( platelet count &lt; 150,000/mm3 , age ) . 4 . INR PT &gt; 2X upper limit normal PTT &gt; 2.33X upper limit normal ( patient correctable deficiency control medication exclude ) . 5 . Cytogenetic abnormality peripheral blood bone marrow amniotic fluid ( available ) . 6 . Prior allogeneic HSCT cytoreductive conditioning 3 . Infectious . Evidence active opportunistic infection infection HIV1 , hepatitis B , Hepatitis C , parvovirus B 19 DNA PCR within 3090 day prior bone marrow harvest . If infection present , must control ( e.g . stable decrease viral load ) time screen 4 . Pulmonary 1 . Resting O2 saturation pulse oximetry &lt; 95 % room air . 2 . Chest xray indicate active progressive pulmonary disease . 5 . Cardiac 1 . Abnormal electrocardiogram ( EKG ) indicate cardiac pathology . 2 . Uncorrected congenital cardiac malformation clinical symptomatology . 3 . Active cardiac disease , include clinical evidence congestive heart failure , cyanosis , hypotension . 4 . Poor cardiac function evidence LV ejection fraction &lt; 40 % echocardiogram . 6 . Neurologic 1 . Significant neurologic abnormality examination . 2 . Uncontrolled seizure disorder . 7 . Renal 1 . Renal insufficiency : serum creatinine &gt; = 1.2 mg/dl , &gt; = 3+ proteinuria . 2 . Abnormal serum sodium , potassium , calcium , magnesium , phosphate grade III IV Division AIDS Toxicity Scale . 8 . Hepatic/GI : 1 . Serum transaminases &gt; 5X upper limit normal ( ULN ) . 2 . Serum bilirubin &gt; 2X ULN . 3 . Serum glucose &gt; 1.5x ULN . 4 . Intractable severe diarrhea . 9 . Oncologic 1 . Evidence active malignant disease dermatofibrosarcoma protuberans ( DFSP ) 2 . Evidence DFSP expect require antineoplastic therapy within 5 year follow infusion genetically correct cell 3 . Evidence DFSP expect life limit within 5 year follow infusion genetically correct cell 10 . Known sensitivity Busulfan 11 . General 1 . Expected survival &lt; 6 month . 2 . Pregnant . 3 . Major congenital anomaly . 4 . Ineligible autologous HSCT criterion clinical site . 5 . Other condition opinion principal investigator and/or coinvestigators , contraindicate bone marrow harvest , administration busulfan , infusion transduce cell indicate patient patient 's parents/primary caregiver inability follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>gene therapy , hematopoietic stem cell , SCID , lentivirus</keyword>
</DOC>